Ipsen
Ipsen is a French pharmaceutical company headquartered in Paris, France. 

It develops and markets medications used in oncology, neuroscience and rare diseases along with consumer healthcare products. 

It is publicly traded on the Euronext Paris as part of the SBF 120 index.

Ipsen has about 5,700 employees worldwide.

It was created by Henri Beaufour.

It later expanded around the world, including communist Russia and many other countries

Overview

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €2.2 billion in 2018. 

The Beaufour family, which ranks as the 42nd richest family in France, still owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.

In 2018, Ipsen spent close to €302 million—13.5% of consolidated sales—on research and development.

In February 2015, the company announced it would Canbex Therapeutics $6.8 million upfront upon completion of a Phase IIA study of Canbex's lead multiple sclerosis compound, VSN16R.

in October 2016, European Commission approves Ipsen's Cabometyx (Cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

The CABOSUN study, presented at the European Society for Medical Oncology (ESMO) 2016 congress, showed Cabometyx (Cabozantinib) can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma (RCC).

In November 2018, the European Commission (EC) approved Cabometyx (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of Cabometyx (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland. 

In February 2019, Ipsen announced it would acquire Clementia Pharmaceuticals, a biopharmaceutical company specialized in rare bone diseases, for $1.3 billion. This acquisition is the largest in the history of Ipsen. In April 2019, Ipsen announced the deal was finalized.

Research and development
In 2018, Ipsen's R&D expenditure totaled close to €302 million, representing more than 13.5% of group sales.

Ipsen's main research and development centers are located in Cambridge (Massachusetts, United States), Milton Park / Oxford (United Kingdom) and Paris Saclay (France).

Governance

Board of directors
The board of directors sets the strategic guidelines for Ipsen's activities and oversees implementation.
Marc de Garidel, chairman of the board of directors
Anne Beaufour
Henri Beaufour
Philippe Bonhomme
Antoine Flochel (vice-chairman).
Margaret A. Liu
Michèle OLLIER
Paul Sekhri
Carol Stuckley
Piet Wigerinck
Carol Xueref

Management team
Corporate executives are responsible for managing the group's operations and coordinating the group's various scientific, legal, financial, commercial and strategic actions.
Aymeric Le Chatelier, CEO as of January 2019.
François Garnier, executive vice president, general counsel
Benoît Hennion, executive vice president, consumer healthcare
Dominique Laymand, executive vice president, chief ethics and compliance officer
Dr Alexandre Lebeaut, executive vice president, research and development, chief scientific officer
Ivana Magovcevic-Liebisch, executive vice president, chief business officer
Christopher Masterson, senior vice-president, quality
Régis Mulot, executive vice president, chief human resources officer 
Aidan Murphy, executive vice president, technical operations
Richard Paulson, executive vice president, chief executive officer in Ipsen North America
Harout Semerjian, executive vice president, chief commercial officer
Christian Marcoux, senior vice president, global communications
Heather White, vice president, global internal audit

Ipsen Foundation
In 1983, Ipsen founded the Ipsen Foundation (Fondation Ipsen) with the help of the Fondation de France to track progress in biomedical research. It is headquartered in Boulogne-Billancourt. It has organised 64 colloquia, and it has partnered with the World Health Organization, the Fondation Nationale de Gérontologie, Harvard University, the Salk Institute for Biological Studies, the Massachusetts General Hospital, and the academic journals Nature and Cell.